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A B S T R A C T
This paper reviews the advances in understanding of fibrinogen structure and function, its genetic and environ-
mental determinants, role in the process of hemostasis, platelet aggregation, plasma viscosity and erythrocyte aggrega-
tion, cellular and matrix interactions, inflammation, wound healing, tumor development, atherogenesis and involve-
ment in pathogenesis of diseases, that have been made over the past decade. Future studies will seek to define precise
mechanisms of complex gene-environment interactions that influence fibrinogen levels and its complex role in the
pathogenesis of fibrinogen-associated diseases.
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Introduction
Fibrinogen is a soluble glycoprotein present in plas-
ma that has a variety of physiological functions. Fibri-
nogen has an important role in the process of thrombus
formation and evolution. It is a major determinant of
blood viscosity and erythrocyte aggregation. Fibrinogen
is both constitutively expressed and inducible during a
reaction of acute phase. It is also important in cellular
and matrix interactions, wound healing, inflammation,
tumor development and atherogenesis.
The recent years have considerably advanced our un-
derstanding of fibrinogen structure, functions, genetic
and extrinsic determinants and involvement in patho-
genesis of many disease conditions. This paper reviews
the progress made over the past decade.
Search Strategy
A search of papers published during the last decade
(1995–2004) in journals indexed by Current Contents
was performed using the search terms »fibrinogen« in
combination with either »structure«, »hemostasis«, »in-
flammation«, »atherosclerosis«, »genetics«, »environment«,
»smoking«, »obesity«, »disease«, etc., to cover the range of
subtopics in this review.
Fibrinogen Structure
Fibrinogen is a complex multifunctional glycoprotein
composed of two identical molecular halves, each con-
sisting of three non-identical subunit polypeptides des-
ignated as alpha (), beta (	), and gamma () chains held
together by multiple disulfide bridges1. Fibrinogen has
a trinodular structure; one central dimeric E domain in
which each dimer contains the three amino-terminal re-
gions of polypeptides, and two distal D domains. These
three nodules are linked by two coiled-coil regions2 and
contain multiple binding sites3. The amino terminal
ends of  and 	 chains represent fibrinopeptides A and B
(FPA and FPB).
Most of the fibrinogen is found in plasma, where it
exists as a population of slightly different molecules3.
Under normal conditions, about 70% of the fibrinogen
molecules are high molecular weight fibrinogen (HMW-
fibrinogen), with molecular weight (mw) of 340,000 Dal-
ton (Da). The remaining molecules are the consequence
of the proteolysis of the  chains of fibrinogen molecule4:
loss of the C-terminal end of one  chain creates low
weight fibrinogen (LMW-fibrinogen, mw 305,000 Da,
about 26% of total fibrinogen), and loss of both  chains
creates LMW’-fibrinogen (mw 270,000 Da, about 4% of
total fibrinogen)5,6, resulting in impaired fibrin poly-
merization7.
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Physiology and Patophysiology
Fibrinogen has a biological half-life of about 100
hours, and is synthesized predominantly in the liver8,
but also in megakariocytes3. The production of fibri-
nogen by lung and intestinal epithelium requires an in-
flammatory stimulus9. Fibrinogen polypeptide chains ,
	, and  are encoded by three different genes named , 	,
and , clustered on the chromosome 4 in region q23–32
of approximately 50 kb, with the direction of transcrip-
tion of the 	 gene opposite to that of the other two10,11.
Many cytokines and other molecules influence biosyn-
thesis of fibrinogen. For example, interleukin 1 and 6
(Il-1 and Il-6), tissue necrosis factor  (TNF-), free
fatty acids and oncostatin M stimulate fibrinogen syn-
thesis, while interleukin 4, 10, and 13 (Il-4, Il-10, and
Il-13), vitamin E, and high plasma albumin decrease
synthesis of fibrinogen12–14. Fibrinogen and cholesterol
may share a novel common regulatory pathway, because
oxysterols, which suppress cholesterol biosynthesis and
the uptake of LDL-cholesterol, also down-regulates con-
stitutive fibrinogen expression15. It is accepted that the
normal range of plasma levels of fibrinogen is from 1.5
to 3.5 g/l16.
Thrombogenesis
Fibrinogen has an important role in the process of
thrombogenesis, being the precursor of fibrin. Indeed,
most of fibrinogen functions are assigned to certain
structures of fibrin including double-stranded fibrin pro-
tofibrils and highly cross-linked fibrin networks. Fibrin
formation is a series of highly ordered molecular inter-
actions – a complex cascade of enzymatic reactions of
blood coagulation. That cascade is comprised of two
arms, the intrinsic and extrinsic pathways, that con-
verge at factor Xa to form the common pathway. Factor
Xa activates prothrombin to thrombin. Thrombin, which
is a protease enzyme, induces cleavage of FPA from 
chain, what is considered to be the initial step in the
conversion of fibrinogen to fibrin. Removal of the FPA
and also FPB from the fibrinogen  and 	 chains leads
to spontaneous polymerization of the monomers. Lat-
eral growth produces protofibrils, and cross-linking fur-
ther creates fibrin strands. Thrombin-activated factor
XIIIa introduces covalent cross links into polymers to
complete and stabilize the formed thrombi2,17. Fibrino-
gen and fibrin are degraded by plasmin, an enzyme that
is activated from plasminogen18. High fibrinogen levels
lead to formation of larger and less lysable clot with
tight and rigid network structure19,20. Moreover, elevated
fibrinogen levels interact with the binding of plasmi-
nogen to its receptor, causing impaired fibrinolysis21.
Platelet aggregation
The interaction of platelets with fibrinogen is an im-
portant event in the maintenance of haemostatic re-
sponse. Fibrinogen binding to the GP IIb–IIIa receptor
in activated platelets leads to platelet aggregation and
formation of platelet-rich thrombi22–25.
Plasma viscosity and erythrocyte aggregation
Fibrinogen is the major determinant of plasma vis-
cosity and erythrocyte aggregation. Therefore, the rheo-
logical properties of the blood are adversely influenced
by high plasma fibrinogen26. Increased viscosity may,
for example, lead to impaired microcirculatory flow, en-
dothelial damage and thrombosis predisposition27.
Atherogenesis
Fibrinogen binding to intercellular adhesion mole-
cule-1 (ICAM-1 – cell surface glycoprotein important in
cell to cell adhesion interactions) up-regulates ICAM-1
gene expression, mediates the attachment of leukocytes,
macrophages, and platelets to endothelial cells, and
causes the release of vasoactive mediators28,29. More-
over, fibrinogen and its degradation products modulate
endothelial permeability, leading to fibrinogen and fi-
brin deposition in subendothelial space, promoting smooth
muscle cell proliferation and migration and chemotaxis
of monocytes. Fibrinogen and fibrin subendothelial de-
positions provide an adsorptive surface for extracellular
accumulation of LDL and apo(a)30,31. Fibrinogen accu-
mulates in atherosclerotic plaques32. Through all these
effects, fibrinogen may be involved in development of
atherogenesis33. However, in studies with experimental
animals, fibrinogen-deficient mice remained capable of
forming atheromatous plaques34, and a mouse strain
over-expressing fibrinogen did not show increase in de-
gree of atherosclerosis32. Although the conclusions from
such animal models cannot be readily extrapolated to
human arterial disease, such data still represent the ev-
idence that a hypothesis about the causal function of
fibrinogen in the etiology of atherosclerosis needs to be
taken with caution.
Inflammation
Inflammatory process plays an important role in ar-
terial disease, including atherosclerosis. It was found
that fibrinogen regulates NF-kappaB activation and ex-
pression of inflammatory chemokines in endothelial
cells, and therefore may be involved in mediation of in-
flammatory process35. Fibrinogen has another function
in the process of inflammation through binding to its
integrin receptor on the surface of leukocytes, facilitat-
ing chemotactic response, increasing phagocytosis, anti-
body-mediated leukocyte toxicity and delay in apop-
tosis36,37. Fibrinogen is also an acute phase reactant
up-regulated by cytokines like interleukin 6 (Il-6) and
by glucocorticoids38,39. In addition to the increased fibri-
nogen hepatic synthesis in acute response40, intestine
and lung epithelium synthesize fibrinogen after exposure
to inflammatory mediators9. Fibrinogen also appears to
have antioxidant properties41, like some other acute phase
proteins, and may act as a supplementary antioxidant
defense mechanism against oxidative stress arising from
inflammatory conditions42. Such findings do not seem to
support the postulation that fibrinogen is pro-athero-
sclerotic agent41. Therefore, the question whether fibri-
nogen is only a marker of the inflammatory process in-
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volved in atherosclerosis or a mediator (i.e., a pathogenic
factor), is yet to be answered32.
Tumors
Fibrinogen is found deposited in the majority of hu-
man and experimental animal tumors43, suggesting
that fibrinogen and its related products are important
in formation of the stroma. Vascular permeability factor
(VPF), also known as vascular endothelial growth factor
(VEGF), is a multifunctional cytokine expressed and se-
creted at high levels by many tumor cells. Its presumed
role is promotion of extravasation of plasma fibrinogen,
leading to fibrin deposition that alters extracellular ma-
trix of the tumor44. Fibrinogen has been demonstrated
to determine metastatic potential of solid tumors, facili-
tating the stable adhesion and survival of metastatic
emboli after tumor cell intravasation45,46. For example,
in the study of the high grade bladder tumor, malignant
cell lines express ICAM-1, and this expression induces a
fibrinogen-mediated migration47.
Wound healing
It has been proposed that fibrinogen plays an impor-
tant role in wound healing. Fibrinogen seems to contrib-
ute significantly to cell-cell and cell-extracellular matrix
interactions1,48. Although tissue repair and the forma-
tion of fibrotic scar can proceed in the absence of
fibrinogen, it is important for appropriate cellular mi-
gration and organization within wound fields, as well as
initial establishment of wound strength and stability49.
Fibrinogen also promotes vasoconstriction at sites of
vessel wall injury1.
Genetic Determinants of Plasma
Fibrinogen Levels
The genetic determinants of fibrinogen levels un-
doubtedly exist, although different studies reported dif-
ferent degrees of heritability of fibrinogen levels. This
may be explained by polygenic determination of fibri-
nogen levels, reflecting its many roles in biochemical
pathways. Genetic factors have been reported to explain
20–51% of variation in plasma fibrinogen levels50,51.
Various polymorphisms have been identified in all
three , 	, and  fibrinogen genes11. However, the 	-chain
gene has been more extensively studied because in vitro
studies have suggested that its synthesis is the limiting
step in the production of mature fibrinogen52. Several
	-chain gene polymorphisms have been identified (–455
G/A, –148 C/T, –854 G/A, Arg 448 Lys…), which are as-
sociated with increased fibrinogen plasma levels25. The
promoter polymorphisms are in strong linkage disequi-
librium with each other53. The –455 G/A mutation in the
promoter region of the 	 fibrinogen gene is one of the
most common genetic variations, present in up to 20% of
general population and associated with 7–10% higher
levels of fibrinogen than in persons with the GG genotype54.
However, certain effects of 	-chain gene polymorphism
alone are modest and difficult to detect in populati-
on-based studies. They may be much greater in interac-
tion with other extrinsic factors55. Moreover, several
studies reported conflicting results, failing to demon-
strate association of fibrinogen levels with some poly-
morphisms of , 	, and  fibrinogen genes56. Therefore,
the precise role of genetic polymorphisms and their clini-
cal significance still remains unclear, and there is in-
creasing evidence of the importance of gene-environ-
ment interactions in determination of plasma fibrino-
gen levels25.
Extrinsic Determinants of Plasma
Fibrinogen Levels
Smoking
Smoking has been identified as one of the most im-
portant determinants of fibrinogen levels in general
population57. Cigarette smoking markedly increases
plasma fibrinogen levels57,58, as well as the shift from
cigarette to cigar smoking59. Furthermore, passive smo-
king is also associated with increased plasma fibrinogen
levels (to the levels of about 40–60% of those in active
smokers)60. It has been estimated that up to 50% of the
increase in cardiovascular disease risk in smokers
might be attributable to the effects of smoking on fibri-
nogen59,61. Although cessation from smoking results in a
rapid reduction in plasma fibrinogen levels62, the over-
all level still remains increased59. It is estimated that it
takes at least ten years after the cessation of smoking
for fibrinogen levels to equal those of never-smokers.
Former smokers usually have levels of fibrinogen be-
tween those of active and never-smokers63.
Some studies proposed that increased fibrinogen syn-
thesis plays a primary role in the hyperfibrinogenaemia
in smokers64. Such effect of smoking to fibrinogen syn-
thesis could be partly explained as a generalized inflam-
matory response to smoking (chronic inflammatory state
of blood vessels, respiratory tract or other organs)64.
Alcohol
Moderate alcohol consumption significantly decre-
ases plasma fibrinogen levels65. Alcohol intake is thought
to lower risk of coronary heart disease66, what could be
explained partly by an anti-inflammatory action of al-
cohol65. It was observed that alcohol inhibits platelet ad-
hesion to fibrinogen-coated surface under flow67. In ani-
mal experimental studies, moderate levels of alcohol
influenced genetic expression of fibrinogen in the he-
patic cells68. However, the precise mechanism by which
alcohol consumption lowers plasma fibrinogen levels re-
mains unclear.
Fish oil
The beneficial effect of dietary fish oil, rich in omega-
-3 polyunsaturated fatty acids, on cardiovascular dis-
ease is multifactorial, and partly due to their anticoagulant
action. Dietary omega-3 polyunsaturated fatty acids
provoke a hypocoagulant effects in humans, associated
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with influence on fibrinogen levels69. Similarly, omega-
-3-rich fish oils are thought to partly compensate the ad-
verse effects of smoking, including its impact on fibri-
nogen70.
Obesity
Obesity is associated with increased plasma fibri-
nogen concentration71–73. It has been suggested that
there is a direct mechanism by which adipose tissue
might regulate the levels of fibrinogen74, proposing the
secretion of Il-6 by adipose tissue as one of the possible
mechanisms73. In addition, weight reduction can de-
crease plasma fibrinogen72.
Exercise
Available evidence suggests that exercise and physi-
cal training evoke multiple effects on blood hemostasis
in healthy subjects and in patients. A single exercise is
usually associated with a transient increase in blood co-
agulation. However, the effects of acute exercise on
plasma fibrinogen are not clear, as the studies reported
conflicting results75–77. Moderate but regular exercise,
however, reduces plasma fibrinogen levels32,76. It was
observed that moderate exercise appears to enhance
blood fibrinolytic activity without a concomitant activa-
tion of blood coagulation mechanisms, whereas a very
heavy exercise induces simultaneous activation of blood
fibrinolysis and coagulation75. Moreover, plasma fibri-
nogen concentration returns to baseline values after
sedentary activity is resumed77.
Age
Older age is associated with increased plasma fibri-
nogen levels71,78. The proposed mechanism for this asso-
ciation is a slower rate of disposal of fibrinogen with
aging79. However, some studies found that advanced age
is associated with elevated Il-6, possibly suggesting an-
other mechanism for fibrinogen elevation in the process
of ageing78.
Gender
Although occasional reports did not confirmed a sig-
nificant gender differences in plasma fibrinogen levels80,
in majority of papers fibrinogen levels in women were
generally higher that those in men 25,32,81.
Oral contraceptives and hormone
replacement therapy
A number of studies demonstrated that oral contra-
ceptives (OC) are associated with increased fibrinogen
levels82. Younger users have greater level of increase
than older ones, while dosage and estrogen content, as
well as duration of use, are both positively associated
with the increase in fibrinogen concentration81. Plasma
fibrinogen returns to normal value after cessation of
taking OC82. Plasma fibrinogen levels tend to increase
after menopause. Some studies showed that hormone
replacement therapy lowers plasma fibrinogen83, but
this was not consistently confirmed in other reports84,85.
Pregnancy
The levels of coagulation factors are increased in
pregnancy, especially during the third trimester. The
highest level of fibrinogen was observed before the de-
livery and during a first few days afterwards39. That
may be explained partly by hormonal changes, but its
cause is obviously multifactorial, including maternal in-
flammatory response to the conceptus and generalized
acute phase response after delivery39,86.
Low birth weight
Low birth weight is associated with an increased risk
of atherothrombosis, which may be partly related to in-
creased plasma levels of fibrinogen87. It was reported
that reduced growth during fetal life and infancy is re-
lated to high plasma fibrinogen in adult life88. Other re-
ports showed that the association between birth weight
and plasma fibrinogen is abolished after the elimination
of genetic influences, and therefore this association has
underlying genetic causes. According to these studies,
improvement of intrauterine nutrition may not lower
fibrinogen levels in later life87.
Stress and socioeconomic factors
Stress may trigger the hypercoagulable state evi-
denced by an increased plasmatic fibrinogen level89. It
was noted that in healthy subjects acute mental stress
simultaneously activates coagulation (including fibri-
nogen) and fibrinolysis. However, in patients with athe-
rosclerosis and impaired endothelial function, procoa-
gulant responses to acute stress are stronger than
anticoagulant mechanisms and thereby promote a hy-
percoagulable state90. Chronic psychosocial stressors
(as it was proposed to be, for example, low socioeconomic
status) are related to a hypercoagulable state90. Indeed,
concentrations of fibrinogen decreased substantially
with increasing socioeconomic status. Circumstances
earlier in life concerning childhood environment (fa-
ther’s social class, participant’s education) were inver-
sely associated with adult fibrinogen levels91. Therefore,
elevation in plasma fibrinogen may be one of the path-
ways through which low socioeconomic status increases
cardiovascular disease risk92. Adverse job characteris-
tics might also be related to increased plasma fibri-
nogen91. Other studies could not demonstrate strong
correlation between job strain and plasma fibrinogen93,94.
Air pollution
It has been suggested that association between air
pollution, possibly from traffic, and risk of cardiovascu-
lar events may be at least partly mediated through in-
creased concentrations of plasma fibrinogen, possibly
due to an inflammatory reaction caused by air pol-
lution95. Furthermore, another study observed an in-
crease in both Il-6 and fibrinogen concentrations during
a working shift for both smoking and non-smoking tun-
nel construction workers96.
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Seasonality
A seasonal variation of plasma fibrinogen with high-
er values in winter has been observed in some studies97.
Such finding has been attributed to an increase in respi-
ratory tract infections during winter, but other papers
provided no evidence that winter infections could be
held responsible for seasonal variation in fibrinogen
levels97,98. Although some authors found that fibrinogen
displayed a circadian rhythm, with the highest values
in the morning99, others found no diurnal variation in
plasma fibrinogen100.
Infection
Studies investigating an association between fibri-
nogen levels and chronic infection with Helicobacter
pylori and/or with Chlamydia pneumoniae have yielded
inconsistent results101–104. After the first positive re-
ports, further analyses suggested no clear correlation
between fibrinogen concentration and these infectious
agents25.
Chronic inflammation
Chronic inflammations, such as periodontal disease
or smoking-induced lung injuries, have been reported to
have a potential to induce chronic increase of Il-6 and
consequently elevation of fibrinogen levels98,105.
Drugs
There are many drugs that decrease fibrinogen levels,
such as beta-adrenergic receptor blockers, ACE-inhibi-
tors, calcium channel blockers, fibrinolytics, ticlopidine
and pentoxifyline25,32,106,107 (Table 1). Fibrates are lipid-
-modifying agents that act through the nuclear receptor
peroxisome proliferator-activated receptor alpha (PPA-
-R)108. In addition, most fibrates also consistently low-
er plasma fibrinogen levels109. Fibrates were reported to
diminish basal and Il-6-induced fibrinogen-beta pro-
moter activity108. Interestingly, statins (which form other
major group of hypolipemic drugs – HMG CoA reductase
inhibitors), that currently largely replace fibrates be-
cause of better clinical results in treatment of cardiovas-
cular disease32, generally do not decrease fibrinogen
levels32,110–114. Although a large number of drugs is
known to interfere with fibrinogen metabolism, decreas-
ing its plasma concentration, there is still no single
known drug that would selectively lower fibrinogen
level25,32.
Fibrinogen and Human Disease
Fibrinogen is thought to be involved in many disease
conditions, either as a direct pathogen factor, prognostic
risk marker, or as a mediator of inflammation associ-
ated with disease pathogenesis.
Congenital afibrinogenemia and
dysfibrinogenaemias
Congenital afibrinogenemia is a rare coagulation dis-
order with autosomal recessive mode of inheritance,
characterized by a complete absence or extremely re-
duced levels of fibrinogen in patients’ plasma and plate-
lets. Clinical manifestations range from minimal bleed-
ing to catastrophic hemorrhage, and patients seem to be
especially susceptible to spontaneous rupture of the
spleen115,116.
The dysfibrinogenaemias are disorders character-
ized by structural abnormalities in the fibrinogen mole-
cule. They are mostly inherited (traditionally named af-
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ter the location of their discovery or after the place of
residency of the patient), but could be also acquired as a
result of underlying hepatic disease. The structural
modifications result in alterations in fibrinopeptide re-
lease, fibrin polymerization, cross-linking or fibrino-
lysis. However, approximately 55% of patients are
asymptomatic, 25% have bleeding tendency and around
20% have thrombotic complications117.
Cardiovascular disease
The notion that fibrinogen is strongly, consistently,
and independently related to cardiovascular disease
risk has been extensively studied and widely accepted.
The evidence is based on numerous prospective epide-
miological and clinical studies, clinical observations,
and meta-analyses52,118–120. In the PRIME study, classic
risk factors explained 25% of the excess risk of coronary
heart disease in Belfast compared with France, while
fibrinogen alone accounted for 30% 121. Another example
is the Strong Heart Study where in adults without clini-
cal evidence of coronary artery disease fibrinogen levels
predicted later cardiovascular events and target organ
damage independently of conventional risk factors 122,
123. Increased levels of troponin and fibrinogen were
found to be independently associated with unfavorable
course of patients with acute coronary syndrome124. It
was also found that fibrinogen concentrations measured
during the acute phase of myocardial infarction were as-
sociated with cardiovascular death or a new myocardial
infarction 125, being an independent short-term predic-
tor of mortality126,127. Fibrinogen levels on admission to
hospital might have an important value for risk stratifi-
cation and more aggressive reduction of infarct size in
patients who are treated with primary angioplasty128. It
was also observed that increased pre-procedural fibri-
nogen level should be considered as a strong predictor
for re-stenosis after coronary stenting, as well as high
fibrinogen levels after coronary balloon angioplasty129.
Recently published study showed that plasma fibri-
nogen levels are associated with a strong family history
of myocardial infarction130. In that work subjects with a
parental and sibling history of myocardial infarction
had higher plasma fibrinogen levels, and also higher
prevalence of angina pectoris, than the matched con-
trols130. Another study demonstrated a significant in-
crease in fibrinogen levels in the healthy, male, first-de-
gree relatives of patients with severe coronary artery
disease131. Therefore, plasma fibrinogen levels may in-
dicate an inheritable risk for cardiovascular disease in
subjects with a strong family history of myocardial
infarction130, but it may also be of particular importance
in subjects who, other than their family history, appear
to be at low risk concerning traditional coronary artery
disease risk factors131. Another possible role of fibri-
nogen was observed in high risk patients with periph-
eral artery disease, where elevated fibrinogen levels in-
dicate an increased risk for poor outcome, particularly
for fatal cardiovascular complications132. Furthermore,
elevated pre-procedural fibrinogen level indicates a
higher risk for restenosis after balloon angioplasty and
stenting of the iliac arteries133.
Despite fibrinogen variability and many factors that
influence its plasma level, the association between fibri-
nogen and cardiovascular disease based on a single
measurement is strong and consistent25. The deleteri-
ous effects of this protein seem to be mediated through
its role in thrombogenesis, hemorrheology, inflamma-
tion, and the atherogenic process itself134. However,
polymorphisms in the human fibrinogen gene with
higher fibrinogen levels do not increase the risk for car-
diovascular disease32,53,135. In addition to that, elevated
preoperative plasma fibrinogen levels, but not the beta-
fibrinogen –455 G/A genotype predict the total mortality
after coronary artery bypass grafting (CABG)136. To-
gether with animal studies earlier described in this
review32,34, such findings indicated that the causal rela-
tionship between fibrinogen levels and atherogenesis
remains uncertain. Some claim that fibrinogen seems to
be a marker rather than a mediator of vascular disea-
se32, while others suggest that fibrinogen levels are
partly »risk« and partly »marker of risk«, playing a role
in the progression of the disease that produces it55.
Other diseases
The association between ischemic stroke and fibri-
nogen is controversial, with different opinions expres-
sed by different authors32,137–142. However, in adults
without clinical manifestations of atherosclerotic dis-
ease, increased fibrinogen was associated with carotid
intima-media thickness independently of a wide range
of other important risk factors, suggesting that plasma
fibrinogen may represent a systemic marker of carotid
atherosclerosis143,144. Increased plasma level of fibri-
nogen is associated with the presence and severity of
target organ damage in patients with essential hyper-
tension. It was proposed that it might contribute to the
development of atherosclerotic disease in these pati-
ents145.
Although increased levels of fibrinogen were posi-
tively correlated to the risk of deep venous thrombosis,
mainly in the elderly146, other reports could not confirm
the correlation between fibrinogen and risk of venous
thrombosis147. There is also mounting evidence that
chronic atrial fibrillation is associated with a prothrom-
botic or hypercoagulable state148, and it was suggested
an independent predictor of abnormal fibrinogen le-
vels149. Some studies suggest that increase in plasma
fibrinogen levels may contribute to the increased risk of
stroke and thromboembolism in atrial fibrillation150.
Increased plasma fibrinogen is also related to re-
duced pulmonary function and increased risk of chronic
obstructive pulmonary disease151. Lung cells express in-
creased levels of Il-6 during acute or chronic inflamma-
tion, and are able to synthesize fibrinogen after an in-
flammatory stimulus. In addition, persistent alveolar
fibrinogen deposition is a morphological hallmark of se-
vere or chronic lung injury9.
D. Pulani} and I. Rudan: The Past Decade: Fibrinogen, Coll. Antropol. 29 (2005) 1: 341–349
346
U:\coll-antropolo\coll-antro-1-2005\pulanic-rudan.vp
17. lipanj 2005 10:35:35
Plate: 6 of 9
Color profile: Disabled
Black  150 lpi at 45 degrees
Significantly elevated fibrinogen levels are observed
in patients with diabetes type I and type II. Insulin defi-
ciency increases fibrinogen biosynthesis, while hyper-
glycemia increases plasma fibrinogen levels107. Fibrino-
gen levels were found to be significantly higher in diabetic
patients with retinopathy or nephropathy than in pa-
tients without these complications152. Metabolic syn-
drome X, a common condition in the general population,
is characterized by dyslipidemia, hypertension, abdominal
obesity, glucose intolerance or non insulin-dependent dia-
betes mellitus. Abnormalities of blood coagulation, in-
cluding higher fibrinogen levels, have also been found in
metabolic syndrome X 153–156.
Increased plasma fibrinogen levels and haemostatic
abnormalities suggesting a prothrombotic state are pre-
sent in patients with end-stage renal disease and could
contribute to increased cardiovascular morbidity in such
patients157–159. Moreover, it was found that elevated
fibrinogen was independently associated with concen-
tric hypertrophy of left ventricle and systolic dysfunc-
tion in patients with end-stage renal disease160. Another
possible clinical implication of fibrinogen was described
in patients with rheumatoid arthritis (RA). It was sug-
gested that in RA fibrinogen correlates better with dis-
ease progression than widely and traditionally used
erythrocyte sedimentation rate, and that it should be
used as a long-term inflammatory marker161.
An association between men with erectile dysfunc-
tion and fibrinogen was observed; such patients who
smoked had significantly increased plasma fibrinogen
concentration in comparison to control smokers. Simi-
larly, men with erectile dysfunction who did not smoke
had higher levels of plasma fibrinogen compared to both
smokers and non-smokers without erectile dysfunction.
These results support the concept that cardiovascular
risk factors are predictors of erectile dysfunction and
that it may be another manifestation of vascular di-
sease162. Another disease condition related to elevated
fibrinogen is pre-eclampsia. Pre-eclampsia is associated
with a state of hypercoagulability together with an in-
crease of fibrinogen concentration. Such findings may
be a reflection of the exaggerated inflammatory re-
sponse and subsequent endothelial activation, which
are believed to be the key pathophysiological mecha-
nisms in pre-eclampsia163. Neoplastic diseases are one
of the leading causes of morbidity and mortality in the
world. Extravascular, intratumoral fibrinogen and fi-
brin depositions are frequently observed within and
around neoplastic tissue and have been implicated in
various aspects of tumor growth and metastasis. A re-
cent data suggested that the plasma fibrinogen level is a
clinically important and useful marker of the extent of
tumor progression in gastric cancer164.
Conclusion
Measurement of the plasma fibrinogen has an impor-
tant role in the clinical setting – at least as a marker for
risk stratifications for disease development or as a marker
of disease status. We may suggest to our patients com-
prehensive lifestyle changes – for example, cessation of
smoking, regularly physical activity and maintaining a
healthy body weight – that will decrease their plasma
fibrinogen levels, together with other beneficial effects.
Fibrinogen is a complex and multifunctional gly-
coprotein that remains an interesting research subject
to scientists from different fields of biomedicine – from
laboratory investigators, through clinicians to epide-
miologists. The knowledge about fibrinogen increased
during the past decade. However, questions that need to
be answered still remain. The association between bene-
ficial effect of lowering plasma fibrinogen concentra-
tions and development of cardiovascular disease and
other pathologic conditions related to increased fibri-
nogen needs to be established and clarified. Further ef-
forts should be invested in defining the precise mecha-
nisms of complex gene-environment interactions that
influence fibrinogen levels and their role in the pa-
thogenesis of the fibrinogen-related diseases. It could be
speculated that possible discovery of a drug that would
specifically lower plasma fibrinogen would also explain
some of these questions in the future.
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PRETHODNO DESETLJE]E: FIBRINOGEN
S A @ E T A K
Ovaj ~lanak iznosi pregled napretka u~injenog tijekom proteklog desetlje}a, u razumijevanju strukture i uloge
fibrinogena, njegovih nasljednih i okoli{nih odrednica, zna~enja u procesu hemostaze, agregacije trombocita, vis-
koznosti plazme, agregacije eritrocita, stani~nih interakcija, upale, cijeljenja rane, razvoja tumora, aterogeneze, te
uloge u patogenezi bolesti. Budu}a }e istra`ivanja nastojati definirati precizne mehanizme kompleksnih me|udjelo-
vanja izme|u nasljednih i okoli{nih ~imbenika koji utje~u na razinu fibrinogena i njegovu slo`enu ulogu u patogenezi
bolesti povezanih s utjecajem fibrinogena.
D. Pulani} and I. Rudan: The Past Decade: Fibrinogen, Coll. Antropol. 29 (2005) 1: 341–349
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